title: Gemcitabine plus paclitaxel may be a promising chemotherapy regimen for metastatic granular cell tumour.
authors.forename: O
authors.initials: O
authors.lastname: Kanat
authors.forename: U
authors.initials: U
authors.lastname: Yalcinkaya
authors.forename: T
authors.initials: T
authors.lastname: Akbunar
authors.forename: E
authors.initials: E
authors.lastname: Kurt
authors.forename: T
authors.initials: T
authors.lastname: Evrensel
authors.forename: O
authors.initials: O
authors.lastname: Manavoglu
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016586:Granular Cell Tumor / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D049268:Positron-Emission Tomography; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine